Cardiac Sympathetic Imaging With mIBG in Heart Failure

JACC-CARDIOVASCULAR IMAGING

卷:3

Article

Carrio, Ignasi¹  Cowie, Martin R.⁵  Yamazaki, Junichi³  Udelson, James²  Camici, Paolo G.^1,4 

[1] Hosp Santa Creu & Sant Pau, Barcelona 08025, Spain

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

[3] Toho Univ, Sch Med, Tokyo, Japan

[4] Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci, London, England

[5] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England

关键词: mIBG;    heart failure;    cardiac sympathetic imaging;    sudden death;    prognosis;   

DOI  :  10.1016/j.jcmg.2009.07.014

来源: Elsevier

【 摘 要 】

Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF. (J Am Coll Cardiol Img 2010;3:92-100) (C) 2010 by the American College of Cardiology Foundation

【 授权许可】

Free